Evidence map›Paper›PMID 33808740›Full record

ArticleCancers2021

A

Nardeen Eldafashi, Rebecca Darlay, Ruchi Shukla, Misti Vanette McCain, Robyn Watson, Yang Lin Liu, Nikki McStraw, Moustafa Fathy, Michael Atef Fawzy, Marco Y W Zaki and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. The role of PD‑1/PD‑L1 axis in liver diseases.Clinical and experimental medicine · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. The PD-1/PD-L1 Axis in the Biology of MASLD.International journal of molecular sciences · 2024
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. A New EGFR Inhibitor fromCurrent issues in molecular biology · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 4 countries.

Nardeen EldafashiTranslational and Clinical Research Institute, Faculty of Medical Sciences, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.
Rebecca DarlayPopulation Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, International Centre for Life, Newcastle upon Tyne NE1 3BZ, UK.
Ruchi ShuklaBiosciences Institute, Faculty of Medical Sciences, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.
Misti Vanette McCainTranslational and Clinical Research Institute, Faculty of Medical Sciences, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.ORCID 0000-0002-1967-0421
Robyn WatsonTranslational and Clinical Research Institute, Faculty of Medical Sciences, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.
Yang Lin LiuTranslational and Clinical Research Institute, Faculty of Medical Sciences, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.
Nikki McStrawBiosciences Institute, Faculty of Medical Sciences, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.
Moustafa FathyBiochemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.ORCID 0000-0002-0734-5007
Michael Atef FawzyBiochemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
Marco Y W ZakiTranslational and Clinical Research Institute, Faculty of Medical Sciences, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.ORCID 0000-0003-3097-5776
Ann K DalyTranslational and Clinical Research Institute, Faculty of Medical Sciences, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.
João P MaurícioTranslational and Clinical Research Institute, Faculty of Medical Sciences, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.ORCID 0000-0002-6853-432X
Alastair D BurtTranslational and Clinical Research Institute, Faculty of Medical Sciences, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.
Beate HaugkDepartment of Cellular Pathology, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle NE1 4LP, UK.
Heather J CordellPopulation Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, International Centre for Life, Newcastle upon Tyne NE1 3BZ, UK.ORCID 0000-0002-1879-5572
Cristiana BiancoTranslational Medicine, Department of Transfusion Medicine and Hematology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.ORCID 0000-0003-4611-6781
Jean-François DufourUniversity Clinic for Visceral Surgery and Medicine, University Hospital of Bern, 3010 Bern, Switzerland.ORCID 0000-0002-8062-1346
Luca ValentiTranslational Medicine, Department of Transfusion Medicine and Hematology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.ORCID 0000-0001-8909-0345
Quentin M AnsteeTranslational and Clinical Research Institute, Faculty of Medical Sciences, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.ORCID 0000-0002-9518-0088
Helen L ReevesTranslational and Clinical Research Institute, Faculty of Medical Sciences, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.
Newcastle University · GBCentre for Life · GBMinia University · EGNewcastle upon Tyne Hospitals NHS Foundation Trust · GBFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITRoyal Victoria Infirmary · GBUniversity of Bern · CHUniversity of Milan · IT

Funding

Cancer Research UK 23390Cancer Research UK 26813Cancer Research UK C18342/A23390Cancer Research UK C9380/A18084Cancer Research UK C9380/A26813
6 · The paper itself

Abstract

Obesity and non-alcoholic fatty liver disease (NAFLD) are contributing to the global rise in deaths from hepatocellular carcinoma (HCC). The pathogenesis of NAFLD-HCC is not well understood. The severity of hepatic steatosis, steatohepatitis and fibrosis are key pathogenic mechanisms, but animal studies suggest altered immune responses are also involved. Genetic studies have so far highlighted a major role of gene variants promoting fat deposition in the liver (

Indexed as

genetic predispositionhepatocellular carcinomametabolic syndromePD-1PDCD1PNPLA3primary liver cancersingle-nucleotide polymorphismTM6SF2

Identifiers

PMID33808740
PMCPMC8003582
OpenAlexW3136697640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.